Refereed journal article or data article (A1)
Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
List of Authors: Mälkönen Tarja, Nuutinen Pauliina, Hallinen Taru, Soini Erkki, Nissinen Riikka, Wennerstöm Christina, Rantanen Tapio, Hagman Johanna H., Harvima Rauno, Höök-Nikanne Johanna, Ilves Tiina, Lintu Päivi, Malanin Ken, Soramäki Iina, Tasanen Kaisa, Teho Arja, Vähävihu Katja, Itälinna Sari, Leinonen Pekka, Sarajärvi Piia, Huilaja Laura, Pasternack Rafael
Publisher: Medical Journals/Acta D-V
Publication year: 2022
Journal: Acta Dermato-Venereologica
Journal name in source: Acta Dermato-Venereologica
Article number: adv00631
Volume number: 102
eISSN: 1651-2057
DOI: http://dx.doi.org/10.2340/actadv.v101.910
URL: https://doi.org/10.2340/actadv.v101.910
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/175034990
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.
Downloadable publication This is an electronic reprint of the original article. |  |
